XBIO Key Statistics, Chart & Performance
The current stock price of XBIO is 2.42 USD. In the past month the price decreased by -39.65%. In the past year, price decreased by -41.05%.
XBIO Latest News, Press Relases and Analysis
XBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About XBIO
Company Profile
Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. The company is headquartered in Framingham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2016-11-07. The firm is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The firm's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. The company is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.
Company Info
XENETIC BIOSCIENCES INC
945 Concord St.
Framingham MASSACHUSETTS 01701 US
CEO: Jeffrey F. Eisenberg
Employees: 2
Phone: 17817787720
XENETIC BIOSCIENCES INC / XBIO FAQ
Can you describe the business of XENETIC BIOSCIENCES INC?
Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. The company is headquartered in Framingham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2016-11-07. The firm is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The firm's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. The company is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.
Can you provide the latest stock price for XENETIC BIOSCIENCES INC?
The current stock price of XBIO is 2.42 USD. The price increased by 4.76% in the last trading session.
What is the dividend status of XENETIC BIOSCIENCES INC?
XBIO does not pay a dividend.
How is the ChartMill rating for XENETIC BIOSCIENCES INC?
XBIO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is XENETIC BIOSCIENCES INC worth?
XENETIC BIOSCIENCES INC (XBIO) has a market capitalization of 5.52M USD. This makes XBIO a Nano Cap stock.
XBIO Technical Analysis
XBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to XBIO. XBIO has a great financial health rating, but its profitability evaluates not so good.
XBIO Financial Highlights
Over the last trailing twelve months XBIO reported a non-GAAP Earnings per Share(EPS) of -2. The EPS increased by 34.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -57.59% | ||
| ROE | -69.28% | ||
| Debt/Equity | 0 |
XBIO Forecast & Estimates
For the next year, analysts expect an EPS growth of 19.04% and a revenue growth 13.64% for XBIO